Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.
The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.